410 related articles for article (PubMed ID: 32264820)
21. Erenumab: A First-in-Class Monoclonal Antibody for Migraine Prevention.
Garland SG; Smith SM; Gums JG
Ann Pharmacother; 2019 Sep; 53(9):933-939. PubMed ID: 30813769
[No Abstract] [Full Text] [Related]
22. Multidimensional assessment of the effects of erenumab in chronic migraine patients with previous unsuccessful preventive treatments: a comprehensive real-world experience.
Russo A; Silvestro M; Scotto di Clemente F; Trojsi F; Bisecco A; Bonavita S; Tessitore A; Tedeschi G
J Headache Pain; 2020 Jun; 21(1):69. PubMed ID: 32517693
[TBL] [Abstract][Full Text] [Related]
23. Efficacy and safety of erenumab (AMG334) in episodic migraine patients with prior preventive treatment failure: A subgroup analysis of a randomized, double-blind, placebo-controlled study.
Goadsby PJ; Paemeleire K; Broessner G; Brandes J; Klatt J; Zhang F; Picard H; Lenz R; Mikol DD
Cephalalgia; 2019 Jun; 39(7):817-826. PubMed ID: 30982348
[TBL] [Abstract][Full Text] [Related]
24. A Controlled Trial of Erenumab for Episodic Migraine.
Goadsby PJ; Reuter U; Hallström Y; Broessner G; Bonner JH; Zhang F; Sapra S; Picard H; Mikol DD; Lenz RA
N Engl J Med; 2017 Nov; 377(22):2123-2132. PubMed ID: 29171821
[TBL] [Abstract][Full Text] [Related]
25. Long-term safety and efficacy of erenumab in patients with chronic migraine: Results from a 52-week, open-label extension study.
Tepper SJ; Ashina M; Reuter U; Brandes JL; Doležil D; Silberstein SD; Winner P; Zhang F; Cheng S; Mikol DD
Cephalalgia; 2020 May; 40(6):543-553. PubMed ID: 32216456
[TBL] [Abstract][Full Text] [Related]
26. Long-term efficacy and safety of erenumab in patients with chronic migraine in whom prior preventive treatments had failed: A subgroup analysis.
Ashina M; Tepper SJ; Brandes JL; Reuter U; Boudreau GP; Weatherall M; Gantenbein AR; Doležil D; Klatt J; Wang A; Karanam AK; Cheng S; Mikol DD
Headache; 2022 May; 62(5):624-633. PubMed ID: 35593783
[TBL] [Abstract][Full Text] [Related]
27. Twelve-month safety, tolerability and susceptibility to adverse events of prophylactic migraine therapy with erenumab: a retrospective real-world study.
Schenk H; Holle D; Nsaka M; Kleinschnitz C; Glas M; Scheffler A
J Headache Pain; 2022 May; 23(1):55. PubMed ID: 35538414
[TBL] [Abstract][Full Text] [Related]
28. Comparing the relative and absolute effect of erenumab: is a 50% response enough? Results from the ESTEEMen study.
Ornello R; Baraldi C; Guerzoni S; Lambru G; Andreou AP; Raffaelli B; Gendolla A; Barbanti P; Aurilia C; Egeo G; Cevoli S; Favoni V; Vernieri F; Altamura C; Russo A; Silvestro M; Valle ED; Mancioli A; Ranieri A; Alfieri G; Latysheva N; Filatova E; Talbot J; Cheng S; Holle D; Scheffler A; Nežádal T; Čtrnáctá D; Šípková J; Matoušová Z; Casalena A; Maddestra M; Viola S; Affaitati G; Giamberardino MA; Pistoia F; Reuter U; Sacco S
J Headache Pain; 2022 Mar; 23(1):38. PubMed ID: 35305579
[TBL] [Abstract][Full Text] [Related]
29. Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial.
Tepper S; Ashina M; Reuter U; Brandes JL; Doležil D; Silberstein S; Winner P; Leonardi D; Mikol D; Lenz R
Lancet Neurol; 2017 Jun; 16(6):425-434. PubMed ID: 28460892
[TBL] [Abstract][Full Text] [Related]
30. Erenumab in highly therapy-refractory migraine patients: First German real-world evidence.
Scheffler A; Messel O; Wurthmann S; Nsaka M; Kleinschnitz C; Glas M; Naegel S; Holle D
J Headache Pain; 2020 Jul; 21(1):84. PubMed ID: 32620151
[TBL] [Abstract][Full Text] [Related]
31. Timing and durability of response to erenumab in patients with episodic migraine.
McAllister PJ; Turner I; Reuter U; Wang A; Scanlon J; Klatt J; Chou DE; Paiva da Silva Lima G
Headache; 2021 Nov; 61(10):1553-1561. PubMed ID: 34841526
[TBL] [Abstract][Full Text] [Related]
32. Safety and tolerability of erenumab in individuals with episodic or chronic migraine across age groups: a pooled analysis of placebo-controlled trials.
Lampl C; Kraus V; Lehner K; Loop B; Chehrenama M; Maczynska Z; Ritter S; Klatt J; Snellman J
J Headache Pain; 2022 Aug; 23(1):104. PubMed ID: 35978286
[TBL] [Abstract][Full Text] [Related]
33. Long-term tolerability and nonvascular safety of erenumab, a novel calcitonin gene-related peptide receptor antagonist for prevention of migraine: A pooled analysis of four placebo-controlled trials with long-term extensions.
Ashina M; Kudrow D; Reuter U; Dolezil D; Silberstein S; Tepper SJ; Xue F; Picard H; Zhang F; Wang A; Zhou Y; Hong F; Klatt J; Mikol DD
Cephalalgia; 2019 Dec; 39(14):1798-1808. PubMed ID: 31707815
[TBL] [Abstract][Full Text] [Related]
34. Long-Term Effectiveness of Three Anti-CGRP Monoclonal Antibodies in Resistant Chronic Migraine Patients Based on the MIDAS score.
Iannone LF; Fattori D; Benemei S; Chiarugi A; Geppetti P; De Cesaris F
CNS Drugs; 2022 Feb; 36(2):191-202. PubMed ID: 35146696
[TBL] [Abstract][Full Text] [Related]
35. Erenumab for episodic migraine prophylaxis.
Overeem LH; Neeb L; Reuter U
Expert Rev Neurother; 2019 Aug; 19(8):751-757. PubMed ID: 30614741
[No Abstract] [Full Text] [Related]
36. Real-world persistence of erenumab for preventive treatment of chronic and episodic migraine: Retrospective real-world study.
Gladstone J; Chhibber S; Minhas J; Neish CS; Power GS; Lan Z; Rochdi D; Lanthier-Martel J; Bastien N
Headache; 2022 Jan; 62(1):78-88. PubMed ID: 34807454
[TBL] [Abstract][Full Text] [Related]
37. Does MIDAS reduction at 3 months predict the outcome of erenumab treatment? A real-world, open-label trial.
De Icco R; Vaghi G; Allena M; Ghiotto N; Guaschino E; Martinelli D; Ahmad L; Corrado M; Bighiani F; Tanganelli F; Bottiroli S; Cammarota F; Sances G; Tassorelli C
J Headache Pain; 2022 Sep; 23(1):123. PubMed ID: 36115947
[TBL] [Abstract][Full Text] [Related]
38. Efficacy and safety of erenumab in women with a history of menstrual migraine.
Pavlovic JM; Paemeleire K; Göbel H; Bonner J; Rapoport A; Kagan R; Zhang F; Picard H; Mikol DD
J Headache Pain; 2020 Aug; 21(1):95. PubMed ID: 32746775
[TBL] [Abstract][Full Text] [Related]
39. Two-year efficacy and safety of erenumab in participants with episodic migraine and 2-4 prior preventive treatment failures: results from the LIBERTY study.
Ferrari MD; Reuter U; Goadsby PJ; Paiva da Silva Lima G; Mondal S; Wen S; Tenenbaum N; Pandhi S; Lanteri-Minet M; Stites T
J Neurol Neurosurg Psychiatry; 2022 Mar; 93(3):254-262. PubMed ID: 34845002
[TBL] [Abstract][Full Text] [Related]
40. Efficacy and safety of erenumab in migraine prevention: evidences from direct and indirect comparisons.
Wang X; He Q; Wen D; Ma L; You C
Neurol Sci; 2022 Apr; 43(4):2751-2758. PubMed ID: 34731334
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
